SCHEMBL649271

SCHEMBL649271

CCCCn1c(C(C)N(Cc2ccccc2)Cc2ccc(C(=O)OC)cc2)cnc1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 5/20 0.42
LPAR1 Q92633 1/20 0.38
LPAR5 Q9H1C0 1/20 0.38
AGTR2 P50052 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
TSHR P16473 1/20 0.38
FAAH O00519 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DRD2 P14416 1/20 0.38
TBXA2R P21731 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650955 0.95 LPAR1 (0.41) AGTR1LPAR1LPAR5ALDH1A1KDM4E
SCHEMBL650145 0.86 LPAR1 (0.40) AGTR1LPAR1LPAR5AGTR2ALDH1A1
SCHEMBL5134636 0.83 AGTR1 (0.46) AGTR1AGTR2ALDH1A1KDM4EMAPT
SCHEMBL14586255 0.82 TSHR (0.46) ALDH1A1KDM4ETSHRKMT2ASMN1; SMN2
SCHEMBL5136262 0.81 TLR7 (0.41) UBE2MDCUN1D1
SCHEMBL5135175 0.80 AGTR1 (0.43) AGTR1LPAR1LPAR5AGTR2ALDH1A1
SCHEMBL5136085 0.79 AGTR1 (0.45) AGTR1LPAR1LPAR5AGTR2ALDH1A1
SCHEMBL650681 0.79 LPAR1 (0.40) AGTR1LPAR1LPAR5ALDH1A1KDM4E
SCHEMBL650693 0.79 LPAR1 (0.40) AGTR1LPAR1LPAR5ALDH1A1KDM4E
SCHEMBL5135309 0.78 TLR7 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed